How long does Desoxypipradrol last?

The total duration of Desoxypipradrol via insufflated is 10 hours to 72 hours. Onset typically occurs within 15 minutes to 4 hours. Peak effects last 6 hours to 30 hours.

Desoxypipradrol — SubstanceWiki

Desoxypipradrol

Substituted piperidines · Stimulants

8 dangerous interactions — combining Desoxypipradrol with certain substances may be life-threatening.

See all

Stimulants(Substituted piperidines)

Quick Dosage

insufflated1.5–3.5 mg (common)

oral2–6 mg (common)

Total duration (insufflated)10hr–72hr

View full details

Desoxypipradrol (2-diphenylmethylpiperidine; 2-DPMP) is a synthetic stimulant of the substituted piperidine chemical class — a structural analog of pipradrol in which the hydroxyl group is removed (desoxy), substantially increasing its potency and dramatically extending its duration of action. It is one of the most extremely long-acting stimulants encountered in the research chemical space, with effects documented to persist for 24–72 hours following a single dose — a duration profile that distinguishes it categorically from virtually all other stimulants and constitutes its defining harm characteristic.

Desoxypipradrol acts primarily as a norepinephrine-dopamine reuptake inhibitor (NDRI) — analogous in mechanism to cocaine and methylphenidate, but with far greater potency and an elimination half-life measured in days rather than hours. Its extreme lipophilicity and resistance to hepatic metabolism are responsible for this extraordinary duration. Community discussions consistently frame 2-DPMP as an "extremely hazardous" stimulant — not because of its acute toxicity profile per se, but because the inability to predict duration and the multiple-day stimulation make sleep deprivation, psychiatric destabilization, and cardiovascular stress virtually inevitable with any non-trivial dose.

The compound achieved notoriety in the UK around 2010–2012 when it appeared in "legal high" products, resulting in a wave of Emergency Department presentations and psychiatric crises due to its unpredictable multi-day stimulation. Its therapeutic window is exceptionally narrow. Even experienced stimulant users report being caught off guard by the duration. Desoxypipradrol should be considered one of the higher-risk stimulant research chemicals available.

How It Feels

The onset of desoxypipradrol is deceptively smooth and alarmingly persistent. Within thirty to sixty minutes of oral ingestion, a calm, focused wakefulness begins to settle in. It does not arrive as a rush or a surge but as a gradual tightening of attention, as though the mind's aperture has been narrowed to admit only what is immediately relevant. Concentration sharpens. Fatigue recedes. There is a sense of clean, functional capability that initially feels productive and even pleasant. The body shows few dramatic signs: heart rate may elevate slightly, appetite diminishes, and there is a subtle sense of physical alertness, but nothing that would seem out of the ordinary to an outside observer.

As the hours pass, the true nature of desoxypipradrol's duration begins to make itself known. What initially felt like a helpful cognitive boost continues without any sign of abating. Three hours in, five hours in, eight hours in, the wakefulness persists with mechanical consistency. The mind remains locked in a state of heightened focus that increasingly feels less like an aid and more like a compulsion. Tasks are completed with efficiency, but the inability to disengage from focused activity becomes its own kind of burden. The experience is not euphoric in any conventional sense. There is no warmth, no rush, no empathogenic glow. Instead, there is a relentless, colorless productivity that strips consciousness down to its most functional elements.

Physically, the effects accumulate gradually. By the twelve-hour mark, the heart rate may be noticeably elevated, sleep is completely impossible, and a growing restlessness begins to infiltrate the previously calm focus. Appetite remains absent. The mouth is dry. There is a subtle but mounting tension in the body that manifests as jaw clenching, fidgeting, and an inability to sit comfortably still. The eyes feel dry and strained from hours of unbroken concentration.

The most notorious aspect of desoxypipradrol is its punishing duration. Effects can persist for twenty-four to forty-eight hours or longer, and the inability to sleep during this time transforms what began as functional stimulation into an ordeal of forced wakefulness. As the hours of sleeplessness accumulate, cognitive function paradoxically deteriorates even as the stimulation continues. Thoughts become repetitive and anxious. Paranoia may emerge. The body aches from sustained tension and immobility. When sleep finally arrives, often only with pharmacological assistance, it is heavy and prolonged, and the recovery period can stretch across several days of fatigue and emotional flatness.

Interactions

Substance	Status	Note
25x-NBOH	Dangerous	—
25x-NBOMe	Dangerous	—
Atropa belladonna	Dangerous	Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Datura	Dangerous	Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Diphenhydramine	Dangerous	Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Harmala alkaloid	Dangerous	Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Peganum harmala	Dangerous	Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
MDMA	Unsafe	—
1,3-Butanediol	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
25E-NBOH	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
2C-T	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
2C-T-2	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
2C-T-21	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
2C-T-7	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
3-FMA	Caution	Increased cardiovascular strain and neurotoxicity risk
4-MMC	Caution	Increased cardiovascular strain and neurotoxicity risk
8-Chlorotheophylline	Caution	Increased cardiovascular strain and neurotoxicity risk
Adrafinil	Caution	Increased cardiovascular strain and neurotoxicity risk
Allylescaline	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Ayahuasca	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Benzydamine	Caution	Increased cardiovascular strain and neurotoxicity risk
Bromantane	Caution	Increased cardiovascular strain and neurotoxicity risk
Cake	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Deschloroetizolam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Desomorphine	Caution	Stimulants mask opioid sedation, increasing overdose risk when the stimulant wears off
DET	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Dichloropane	Caution	Increased cardiovascular strain and neurotoxicity risk
Diclazepam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
DiPT	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
DOM	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
DPT	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Efavirenz	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Ephedrine	Caution	Increased cardiovascular strain and neurotoxicity risk
EPT	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Eszopiclone	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Etizolam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Flubromazepam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Flubromazolam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Flunitrazepam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Flunitrazolam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Gaboxadol	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Hexedrone	Caution	Increased cardiovascular strain and neurotoxicity risk
Ibogaine	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Lorazepam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Mephenaqualone	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
MET	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Methallylescaline	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Methcathinone	Caution	Increased cardiovascular strain and neurotoxicity risk
Metizolam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Midazolam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
MiPT	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
MPT	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Naloxone	Caution	Stimulants mask opioid sedation, increasing overdose risk when the stimulant wears off
Nicotine	Caution	Increased cardiovascular strain and neurotoxicity risk
Nifoxipam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Oxiracetam	Caution	Increased cardiovascular strain and neurotoxicity risk
Pentobarbital	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Phenobarbital	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Phenylpiracetam	Caution	Increased cardiovascular strain and neurotoxicity risk
Psilocybin Mushrooms	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Rhodiola Rosea	Caution	Increased cardiovascular strain and neurotoxicity risk
SAMe	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Alcohol	Uncertain	—

Showing 63 key interactions out of 64 total.

Toxicity & Safety

Duration-Mediated Toxicity: Primary Risk

The primary clinical risk of desoxypipradrol is not acute pharmacological toxicity in the traditional sense, but the consequences of forced multi-day wakefulness:

Severe sleep deprivation: 24–72 hours of enforced wakefulness produces profound cognitive impairment, hallucinations (stimulant psychosis), immune suppression, and cardiovascular stress
Stimulant psychosis: Multiple case reports in UK medical literature document acute psychotic episodes requiring hospitalization following 2-DPMP use, directly attributable to the prolonged stimulation period
Inability to "redose safely": Unlike other stimulants where timing manages the experience, desoxypipradrol's duration makes any redosing during the initial dose's duration period catastrophically dangerous

UK Hospital Experience

The emergence of 2-DPMP in UK "legal high" products (marketed as "Ivory Wave" and similar) in 2010–2012 generated significant Emergency Department data. Case series documented psychosis, severe agitation, self-harm behavior, and cardiac complications requiring hospitalization for multi-day duration symptoms. This real-world data established the compound's clinical danger profile.

Cardiovascular Risk

As a potent NDRI, sustained norepinephrine elevation over 24–72 hours produces prolonged cardiovascular stress — tachycardia, hypertension — with meaningful risk for adverse events particularly in those with cardiac conditions.

No Antagonist

There is no specific antidote or mechanism to accelerate clearance of desoxypipradrol. Supportive care is the only treatment for adverse reactions. Benzodiazepines can partially address anxiety and agitation but cannot reverse the stimulant effect.

Addiction Potential

moderately addictive with a high potential for abuse

Overdose Information

overdose of desoxypipradrol can potentially lead to psychosis more readily than the vast majority of stimulants. Psychotic symptoms from desoxypipradrol can include hearing voices, visual hallucinations, urges to harm oneself, severe anxiety, mania, grandiosity, paranoid delusions, confusion, increased aggression, and irritability.

MDMA** - The neurotoxic effects of MDMA may be increased when combined with other stimulants.
Cocaine** - This combination may increase strain on the heart.
China: As of October 2015, 2-DPMP is a controlled substance in China.
Germany: Desoxypipradrol is controlled under Anlage II BtMG (Narcotics Act, Schedule II) as of December 13, 2014. It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.
Russia: Deoxypipradol is entered in the Schedule I prohibited substance as (Пиперидин-2-ил)дифенилметан.
Switzerland: Desoxypipradol is not controlled under Buchstabe A, B, C and D. It could be considered legal.
United Kingdom: As of November 4, 2010, the UK Home Office announced a ban on the importation of 2-DPMP, following a recommendation from the ACMD. Prior to the import ban, desoxypipradrol was sold as a 'legal high' in several products. Its use lead to several Emergency Department visits which prompted the UK government to commission a review from the ACMD. The Advisory Council on the Misuse of Drugs stated in their report that: "there are serious harms associated with 2-DPMP... typically prolonged agitation (lasting up to 5 days after drug use which is sometimes severe, requiring physical restraint), paranoia, hallucinations and myoclonus (muscle spasms/twitches)." 2-DPMP was due to become a class B drug on March 28, 2012, but the bill was scrapped as two steroids deemed not to be abusable were included in the bill but were later recommended to remain uncontrolled. There was a new discussion about its fate on April 23, 2012, w

Legal Status

China: As of October 2015, 2-DPMP is a controlled substance in China.
Germany: Desoxypipradrol is controlled under Anlage II BtMG (Narcotics Act, Schedule II) as of December 13, 2014. It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.
Russia: Deoxypipradol is entered in the Schedule I prohibited substance as (Пиперидин-2-ил)дифенилметан.
Switzerland: Desoxypipradol is not controlled under Buchstabe A, B, C and D. It could be considered legal.
United Kingdom: As of November 4, 2010, the UK Home Office announced a ban on the importation of 2-DPMP, following a recommendation from the ACMD. Prior to the import ban, desoxypipradrol was sold as a 'legal high' in several products. Its use lead to several Emergency Department visits which prompted the UK government to commission a review from the ACMD. The Advisory Council on the Misuse of Drugs stated in their report that: "there are serious harms associated with 2-DPMP... typically prolonged agitation (lasting up to 5 days after drug use which is sometimes severe, requiring physical restraint), paranoia, hallucinations and myoclonus (muscle spasms/twitches)." 2-DPMP was due to become a class B drug on March 28, 2012, but the bill was scrapped as two steroids deemed not to be abusable were included in the bill but were later recommended to remain uncontrolled. There was a new discussion about its fate on April 23, 2012, where it was decided that the bill would be rewritten and 2-DPMP would still be banned. It was also decided that the bill would be a blanket ban of related chemicals. Desoxypipradrol was eventually made a class B drug and placed in Schedule I on June 13, 2012. There were no recorded deaths from the drug between the banning of its import and the banning of its possession. "Esters and ethers of pipradrol" were controlled with the same amendment as class C drugs.
United States: Desoxypipradrol is unscheduled in the United States, and thus legal to possess and import. However, it is an analog of pipradol which is a Schedule IV Controlled Substance.
Responsible use
Stimulants
Research chemical
Desoxypipradrol (Wikipedia)
Desoxypipradrol (Isomer Design)

Full	develops with prolonged and repeated use
Half	3 - 7 days
Zero	1 - 2 weeks

Desoxypipradrol

Quick Dosage

Dosage

insufflated

oral

Duration

insufflated

oral

How It Feels

Subjective Effects

Physical Effects

Physical(6)

Cognitive & Perceptual Effects

Visual(2)

Cognitive(23)

Pharmacology

Mechanism of Action

Receptor Profile

Pharmacokinetics — Critical Characteristics

Why Duration Is So Extreme

Detection Methods

Standard Drug Panel Inclusion

Urine Detection

Blood and Saliva Detection

Hair Follicle Detection

Confirmatory Testing

Reagent Testing

Interactions

History

Pharmaceutical Origins

Emergence in "Legal Highs" (2010–2012)

Regulatory Response

Legacy

Harm Reduction

Consider Not Using This Compound

If Use Occurs: Microdose Protocol

Never Redose

Harm Reduction During Extended Effects

Context from Reddit

Toxicity & Safety

Duration-Mediated Toxicity: Primary Risk

UK Hospital Experience

Cardiovascular Risk

No Antagonist

Addiction Potential

Overdose Information

Dangerous Interactions

Tolerance

Cross-tolerances

Legal Status

Experience Reports (2)

Tips (6)

Community Discussions (1)

See Also

References (5)

Frequently Asked Questions